Hormonal
The central nervous system (CNS) integrates peripheral adiposity signals (insulin and leptin) and gastrointestinal signals (GLP-1) to regulate both energy balance and glucose homeostasis through overlapping hypothalamic mechanisms.
Your brain acts as a command center for metabolism, listening to hormones like insulin and leptin to decide how to store or burn energy. If these signals are ignored or misinterpreted by the brain (CNS dysfunction), it can lead to obesity and type 2 diabetes, regardless of peripheral efforts.
Growing evidence suggests that nutrient and hormonal signals converge and directly act on brain centers, leading to changes in fuel metabolism and, thus, stable body weight over time. Growing evidence also suggests that these same signals act on the central nervous system (CNS) to regulate glucose metabolism independently.
Why this rating
This is a review article summarizing extensive preclinical and clinical evidence, citing numerous primary studies.
Source
The Integrative Role of CNS Fuel-Sensing Mechanisms in Energy Balance and Glucose Regulation
Darleen A. Sandoval et al. · Annual Review of Physiology · 2007
DOI 10.1146/annurev.physiol.70.120806.095256
More from this paper
- Central administration of GLP-1 reduces food intake and improves glucose tolerance by acting on hypothalamic and hindbrain receptors, independent of peripheral effects.Good
- Hypothalamic AMPK and mTOR act as fuel sensors that integrate energy status signals to regulate food intake and energy expenditure.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →